Due to the lower frequency of recurrent mutations in patients with CLL, patients were grouped by the presence of a protective mutation (in CHD2 and KLHL6 genes) or favorable SCNA (del(13q) as the sole SCNA), and those with an adverse mutation (in NOTCH1, TP53, SF3B1 or BIRC3 genes) or unfavorable SCNA (del(17p) or del(11q)). This evidence concerns the gene BIRC3 and B-cell chronic lymphocytic leukemia.